Application of antioxidant neuroprotectors in complex treatment of insomnia in patients with anxiety and phobic nosogenic disorders
R.S. Remizevich, E.S. Kurasov
Military-Medical Academy, Department of Psychiatry
Were investigated 68 patients with anxiety and phobic nosogenic reactions, which represented a remote period of mental disorders after suffering a cardiac emergency states (hypertensive crises and cardiac arrhythmias). It is shown, that the diagnosis of sleep disorders using polysomnography their prevalence was significantly higher (98,5%), than that according to psychopathological clinical examination (70,6%). The changes of structure (increase in the latent period of II stage and slow wave activity, reduction in the duration of II stage) and some of the quantitative characteristics of sleep (reduction of the general duration, dream fragmentation, gain of backfilling time, frequent awakenings) were established. Found that the use of antioxidant neuroprotector «Meksidol» in the treatment with antidepressants enhances the dynamics of insomnia in the background of the primary treatment.
anxiety and phobic disorders, nosogenic disorders, insomnia, neuroprotectors, treatment.